ロード中...
Natalizumab in pediatric multiple sclerosis patients
Pediatric multiple sclerosis (MS) comprises 2–5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3002661/ https://ncbi.nlm.nih.gov/pubmed/21179619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285610381526 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|